Physician profile
Roberta Barrows
NPI 1922415264
$1,459.83
in general payments reported to CMS, 2019-2025
24 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $102 · 2023: $468 · 2024: $263 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.25 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.48 | 2021-2024 | |
| Edwards Lifesciences Corporation | $132.71 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $111.23 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $98.94 | 2023-2025 | Cds - Mct/Cem Monitoring, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $93.95 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $68.34 | 2023-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.75 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $61.01 | 2021-2025 | Wegovy |
| Xeris Pharmaceuticals, INC. | $55.01 | 2021-2023 | Gvoke Hypopen |
| Lilly USA, LLC | $45.05 | 2022-2025 | Kisunla |
| Dexcom, INC. | $35.36 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $34.61 | 2025 | |
| Abbott Laboratories | $34.08 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.92 | 2023 | Xifaxan |
| Qol Medical, LLC | $25.90 | 2025 | Sucraid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.73 | 2024 | Shingrix |
| Nestle Healthcare Nutrition INC. | $22.61 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.75 | 2023 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $16.88 | 2025 | Uptravi, Opsumit |
| Abiomed | $15.72 | 2024 | Impella |
| Ardelyx, INC. | $15.34 | 2024 | Ibsrela |
| Neurelis, INC. | $14.55 | 2023 | Valtoco |
| Esperion Therapeutics, INC. | $14.53 | 2025 | Nexletol |
| Grt US Holding, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Barrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.